Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals

American Journal of Health-System Pharmacy

Volumn 68, Issue 17, 2011, Pages 1619-1625

  Keel, Rebecca A ^a   Kuti, Joseph L ^a   Sahm, Daniel F ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Antiinfective agents; Ceftazidime; Cilastatin; Doripenem; Dosage; Geriatrics; Imipenem; Injections; Levofloxacin; Meropenem; Minimum inhibitory concentration; Pharmacodynamics; Pharmacokinetics; Piperacillin; Pseudomonas aeruginosa; Pseudomonas infections; Tazobactam

Indexed keywords

CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; DORIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

AGED; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CUMULATIVE FRACTION OF RESPONSE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TREATMENT RESPONSE; UNITED STATES;

EID: 80052698494     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100569     Document Type: Article

References (28)

1. Eagye KJ, Kuti JL, Sutherland CA et al. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin Ther. 2009; 31:2678-88.
2. Obritsch MD, Fish DN, MacLaren R et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive careunit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004; 48:4606-10. (Pubitemid 39577660)
3. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents. 2006; 27:476-81. (Pubitemid 43767087)
4. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Disease Society of America. Clin Infect Dis. 2009; 49:1-12.
5. Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011; 66:227-31.
6. Fluckiger U, Segessenmann C, Gerber AU. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother. 1991; 35:1905-10.
7. Nicolau DP. Pharmacodynamic optimization of β-lactams in the patient care setting. Crit Care. 2008; 12(suppl 4):S2.
8. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003; 22: 982-92.
9. Kuti JL, Ong C, Lo M et al. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2006; 28:62-8. (Pubitemid 43949338)
10. Nicholson S, Peterson J, Pillar CM et al. Activity profile of doripenem, comparator carbapenems, and other antipseudomonal agents in the US: results of CAPITAL 2009 surveillance. Presented at 100th General Meeting of the American Society of Microbiology. San Diego, CA; 2010 May.
11. Ikawa K, Morikawa N, Uehara S et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents. 2009; 33:276-9.
12. Sakka SG, Glauner AK, Bulitta JB et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenemcilastatin in critically ill patients in a randomized controlled trial. Antimicrob Agents Chemother. 2007; 51:3304-10. (Pubitemid 350067544)
13. Crandon JL, Ariano RE, Zelennitsky SS et al. Population pharmacokinetics to determine optimized meropenem dosing regimens in intensive care unit patients over three creatinine clearance (CrCL) ranges. Presented at Annual Meeting of the Society of Critical Care Medicine. Miami, FL; 2010 Jan.
14. Drusano GL, Preston SL, Fowler C et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory ration and the probability of eradication of the infection pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004; 189:1590-7. (Pubitemid 38648286)
15. Young RJ, Lipman J, Gin T et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother. 1997; 40:269-73. (Pubitemid 27394022)
16. Lodise TP, Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam inpatients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother. 2004; 48:4718-24. (Pubitemid 39577677)
17. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 2007; 27:333-42. (Pubitemid 46327901)
18. Passarell JA, Meagher AK, Liolios K et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008; 52:204-10.
19. Crandon JL, Kuti JL, Jones RN et al. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother. 2009; 43:220-7.
20. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat Rev Microbiol. 2004; 2:289-300. (Pubitemid 39490099)
21. Crandon JL, Bulik CC, Kuti JL et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54:1111-6.
22. Crandon JL, Bulik CC, Nicolau DP. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions ofdoripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53:4352-6.
23. Bulik CC, Quintiliani R Jr, Pope JS et al. Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis: a review of 3 cases. Respir Med CME. 2010; 3:146-9.
24. Kuti JL, Moss KM, Nicolau DP et al. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy. 2004; 24:1641-5. (Pubitemid 39426358)
25. Pakyz AL, MacDougall C, Oinonen M et al. Trends in antibacterial use in US academic health centers. Arch Intern Med. 2008; 168:2254-9.
26. Polk RE, Fox C, Mahoney A et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007; 44:664-70.
27. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000; 31(suppl):S131-8. (Pubitemid 32291120)
28. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416.